{
    "root": "0cf064d0-cf65-4112-8817-ed864f16233e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "XENPOZYME",
    "value": "20250303",
    "ingredients": [
        {
            "name": "OLIPUDASE ALFA",
            "code": "6D5766Q4OP"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
            "code": "70WT22SF4B"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        }
    ],
    "indications": "XENPOZYME is indicated for treatment of nonâ€“central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.",
    "contraindications": "See Full Prescribing Information for important recommendations prior to XENPOZYME treatment initiation. ( 2.1 ) Adults: Recommended starting dose is 0.1 mg/kg administered as an intravenous infusion. ( 2.2 ) Pediatrics: Recommended starting dose is 0.03 mg/kg administered as an intravenous infusion. ( 2.3 ) See Full Prescribing Information for the recommended dose escalation and maintenance dosage, dosage modifications to reduce the risk of adverse reactions, and preparation and administration instructions. ( 2.2 , 2.3 , 2.5 , 2.6 , 2.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}